Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas

Ana Fernandez-Teijeiro, Rebecca Betensky, Lisa M. Sturla, John Y H Kim, Pablo Tamayo, Scott L. Pomeroy

Research output: Contribution to journalArticle

Abstract

Purpose: Stratification of risk in patients with medulloblastoma remains a challenge. As clinical parameters have been proven insufficient for accurately defining disease risk, molecular markers have become the focus of interest. Outcome predictions on the basis of microarray gene expression profiles have been the most accurate to date. We ask in a multivariate model whether clinical parameters enhance survival predictions of gene expression profiles. Patients and Methods: In a cohort of 55 young patients (whose medulloblastoma samples have been analyzed previously for gene expression profile), associations between clinical and gene expression variables and survival were assessed using Cox proportional hazards models. Available clinical variables included age, stage (ie, the presence of disseminated disease at diagnosis), sex, histologic subtype, treatment, and status. Results: Univariate analysis demonstrated expression profiles to be the only significant clinical prognostic factor (P = .03). In multivariate analysis, gene expression profiles predicted outcome independent of other criteria. Clinical criteria did not significantly contribute additional information for outcome predictions, although an exploratory analysis noted a trend for decreased survival of patients with metastases at diagnosis but favorable gene expression profile. Conclusion: Gene expression profiling predicts medulloblastoma outcome independent of clinical variables. These results need to be validated in a larger prospective study.

Original languageEnglish (US)
Pages (from-to)994-998
Number of pages5
JournalJournal of Clinical Oncology
Volume22
Issue number6
DOIs
StatePublished - Dec 1 2004

Fingerprint

Medulloblastoma
Transcriptome
Survival
Gene Expression Profiling
Proportional Hazards Models
Multivariate Analysis
Prospective Studies
Neoplasm Metastasis
Gene Expression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. / Fernandez-Teijeiro, Ana; Betensky, Rebecca; Sturla, Lisa M.; Kim, John Y H; Tamayo, Pablo; Pomeroy, Scott L.

In: Journal of Clinical Oncology, Vol. 22, No. 6, 01.12.2004, p. 994-998.

Research output: Contribution to journalArticle

Fernandez-Teijeiro, Ana ; Betensky, Rebecca ; Sturla, Lisa M. ; Kim, John Y H ; Tamayo, Pablo ; Pomeroy, Scott L. / Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 6. pp. 994-998.
@article{810ec5400e40471ebe00b6c5e8483fcc,
title = "Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas",
abstract = "Purpose: Stratification of risk in patients with medulloblastoma remains a challenge. As clinical parameters have been proven insufficient for accurately defining disease risk, molecular markers have become the focus of interest. Outcome predictions on the basis of microarray gene expression profiles have been the most accurate to date. We ask in a multivariate model whether clinical parameters enhance survival predictions of gene expression profiles. Patients and Methods: In a cohort of 55 young patients (whose medulloblastoma samples have been analyzed previously for gene expression profile), associations between clinical and gene expression variables and survival were assessed using Cox proportional hazards models. Available clinical variables included age, stage (ie, the presence of disseminated disease at diagnosis), sex, histologic subtype, treatment, and status. Results: Univariate analysis demonstrated expression profiles to be the only significant clinical prognostic factor (P = .03). In multivariate analysis, gene expression profiles predicted outcome independent of other criteria. Clinical criteria did not significantly contribute additional information for outcome predictions, although an exploratory analysis noted a trend for decreased survival of patients with metastases at diagnosis but favorable gene expression profile. Conclusion: Gene expression profiling predicts medulloblastoma outcome independent of clinical variables. These results need to be validated in a larger prospective study.",
author = "Ana Fernandez-Teijeiro and Rebecca Betensky and Sturla, {Lisa M.} and Kim, {John Y H} and Pablo Tamayo and Pomeroy, {Scott L.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1200/JCO.2004.03.036",
language = "English (US)",
volume = "22",
pages = "994--998",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas

AU - Fernandez-Teijeiro, Ana

AU - Betensky, Rebecca

AU - Sturla, Lisa M.

AU - Kim, John Y H

AU - Tamayo, Pablo

AU - Pomeroy, Scott L.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Purpose: Stratification of risk in patients with medulloblastoma remains a challenge. As clinical parameters have been proven insufficient for accurately defining disease risk, molecular markers have become the focus of interest. Outcome predictions on the basis of microarray gene expression profiles have been the most accurate to date. We ask in a multivariate model whether clinical parameters enhance survival predictions of gene expression profiles. Patients and Methods: In a cohort of 55 young patients (whose medulloblastoma samples have been analyzed previously for gene expression profile), associations between clinical and gene expression variables and survival were assessed using Cox proportional hazards models. Available clinical variables included age, stage (ie, the presence of disseminated disease at diagnosis), sex, histologic subtype, treatment, and status. Results: Univariate analysis demonstrated expression profiles to be the only significant clinical prognostic factor (P = .03). In multivariate analysis, gene expression profiles predicted outcome independent of other criteria. Clinical criteria did not significantly contribute additional information for outcome predictions, although an exploratory analysis noted a trend for decreased survival of patients with metastases at diagnosis but favorable gene expression profile. Conclusion: Gene expression profiling predicts medulloblastoma outcome independent of clinical variables. These results need to be validated in a larger prospective study.

AB - Purpose: Stratification of risk in patients with medulloblastoma remains a challenge. As clinical parameters have been proven insufficient for accurately defining disease risk, molecular markers have become the focus of interest. Outcome predictions on the basis of microarray gene expression profiles have been the most accurate to date. We ask in a multivariate model whether clinical parameters enhance survival predictions of gene expression profiles. Patients and Methods: In a cohort of 55 young patients (whose medulloblastoma samples have been analyzed previously for gene expression profile), associations between clinical and gene expression variables and survival were assessed using Cox proportional hazards models. Available clinical variables included age, stage (ie, the presence of disseminated disease at diagnosis), sex, histologic subtype, treatment, and status. Results: Univariate analysis demonstrated expression profiles to be the only significant clinical prognostic factor (P = .03). In multivariate analysis, gene expression profiles predicted outcome independent of other criteria. Clinical criteria did not significantly contribute additional information for outcome predictions, although an exploratory analysis noted a trend for decreased survival of patients with metastases at diagnosis but favorable gene expression profile. Conclusion: Gene expression profiling predicts medulloblastoma outcome independent of clinical variables. These results need to be validated in a larger prospective study.

UR - http://www.scopus.com/inward/record.url?scp=1842509921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842509921&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.03.036

DO - 10.1200/JCO.2004.03.036

M3 - Article

VL - 22

SP - 994

EP - 998

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -